HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.
Wilson GJ, Church LWP, Kelley CF, Robinson ST, Lu Y, Furch BD, Fong Y, Paez CA, Yacovone M, Jacobsen T, Maughan M, Martik D, Heptinstall JR, Zhang L, Montefiori DC, Tomaras GD, Kublin JG, Corey L.
Wilson GJ, et al.
J Infect Dis. 2024 Dec 13:jiae558. doi: 10.1093/infdis/jiae558. Online ahead of print.
J Infect Dis. 2024.
PMID: 39671174